JO
CGTX icon

John Overdeck’s Cognition Therapeutics CGTX Stock Holding History

John Overdeck’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-19,229
Closed -$14.6K – 5091
2026
Q1 		$14.6K Sell
19,229
-28,500
-60% -$33.2K ﹤0.01% 4520
2025
Q4 		$64.4K Sell
47,729
-49,262
-51% -$80K ﹤0.01% 3906
2025
Q3 		$131K Buy
96,991
+1,792
+2% +$2.44K ﹤0.01% 3435
2025
Q2 		$29.5K Buy
95,199
+12,655
+15% +$4.27K ﹤0.01% 3100
2025
Q1 		$34.7K Buy
82,544
+28,853
+54% +$17K ﹤0.01% 3074
2024
Q4 		$37.7K Buy
53,691
+42,321
+372% +$20.9K ﹤0.01% 3066
2024
Q3 		$5.33K Buy
+11,370
New +$11.7K ﹤0.01% 3063
2023
Q2 		– Sell
-28,236
Closed -$55.9K – 3039
2023
Q1 		$55.9K Sell
28,236
-18,384
-39% -$35K ﹤0.01% 2738
2022
Q4 		$97.9K Buy
46,620
+22,213
+91% +$44.9K ﹤0.01% 2511
2022
Q3 		$46K Buy
+24,407
New +$50.8K ﹤0.01% 2323
2022
Q2 		– Sell
-42,102
Closed -$116K – 2561
2022
Q1 		$116K Sell
42,102
-41,296
-50% -$159K ﹤0.01% 2416
2021
Q4 		$527K Buy
+83,398
New +$813K ﹤0.01% 3205

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.47B AUM 18.73% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

John Overdeck's CGTX Position: Q2 2026 in Review

John Overdeck sold out of Cognition Therapeutics (CGTX) in Q2 2026, closing a stake of 19,229 shares — an estimated $14.6K sold.

John Overdeck first reported a position in CGTX in Q4 2021 and held it in 12 quarters. The position peaked at $527K in Q4 2021. 66 funds tracked by Wall St. Rank hold CGTX as of Q2 2026.

  • John Overdeck reported no remaining Cognition Therapeutics position as of Q2 2026 after selling out during the quarter.
  • John Overdeck sold 19,229 Cognition Therapeutics shares in Q2 2026, an estimated $14.6K.
  • John Overdeck first reported a position in Cognition Therapeutics in Q4 2021 and held it in 12 quarters.
  • John Overdeck's Cognition Therapeutics position peaked at $527K in Q4 2021.
  • 66 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.